Guiding pragmatic treatment choices for rifampicin-resistant tuberculosis in the absence of second-line drug susceptibility testing

Affiliations

• ¹ Department of Global Public Health, Karolinska Institutet, Stockholm, Sweden jay.achar@ki.se.
• ² Desmond Tutu TB Centre, Department of Paediatrics and Child Health, Faculty of Medicine and Health Sciences, Stellenbosch University, Cape Town, South Africa.
• ³ Section of Paediatric Infectious Disease, Department of Infectious Disease, Imperial College London, London, UK.
• ⁴ TB Modelling Group, TB Centre, Centre for Mathematical Modelling of Infectious Diseases and AMR Centre, Department of Infectious Disease Epidemiology, Faculty of Epidemiology and Population Health, London School of Hygiene and Tropical Medicine, London, UK.
• ⁵ School of Health and Related Research, University of Sheffield, Sheffield, UK.
• ⁶ MRC Clinical Trials Unit, University College London, London, UK.
• ⁷ Institute for Global Health, University College London, London, UK.
• ⁸ Wellcome Centre for Infectious Diseases Research in Africa, Institute of Infectious Disease and Molecular Medicine, and Department of Medicine, University of Cape Town, Cape Town, South Africa.